NCT00579826View on ClinicalTrials.gov

Study of Breast Cancer Prevention by Letrozole in High Risk Women

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

March 31, 2015

Study Completion Date

August 31, 2018

Conditions
Breast Cancer
Interventions
DRUG

Letrozole

Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.

DRUG

Placebo

Placebo tablet daily for 6 months then optional open label letrozole for 6 months.

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Carol Fabian, MD

OTHER

NCT00579826 - Study of Breast Cancer Prevention by Letrozole in High Risk Women | Biotech Hunter | Biotech Hunter